Press Release

Statement on Appointment of “Ebola Czar”

PhRMA October 17, 2014

Washington, DC – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today issued the following statement on the selection of Ron Klain to manage the U.S. government’s response to preventing the spread of the Ebola virus:

“Protecting patients and their families from the devastating effects of Ebola is a national priority. As Mr. Klain takes on the important and challenging role of coordinating the government’s response to the Ebola outbreak, our industry stands ready to support these efforts by using our resources and expertise to assist patients and their families affected.

“Stopping the spread of Ebola will require close collaboration and engagement from a wide range of stakeholders, including health care providers, relief organizations, government agencies, and biopharmaceutical companies. Over the past several years, researchers have been working to develop vaccines and treatments to prevent infection and fight its effects, and there are at least two Ebola vaccines currently in the biopharmaceutical pipeline. PhRMA members are also helping to expand capacity on the ground in West Africa to take care of affected patients, including donating medicines, providing funding to relief organizations for infrastructure improvements, medical products and protective equipment for health care workers, and donating funds for disease education and prevention efforts within the region.”

To learn more about the biopharmaceutical industry’s commitment to preventing the spread of Ebola, visit the PhRMA website at as well as the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) website at

 About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.

Find PhRMA Online:

Website –

Facebook –

Blog –

Twitter – and

YouTube –

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit